Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr;28(8):e18153.
doi: 10.1111/jcmm.18153.

RhoA/rho kinase pathway activation in age-associated endothelial cell dysfunction and thrombosis

Iván Palomo  1 , Sergio Wehinger  1 , Vicente Andrés  2   3 , Francisco J García-García  4 , Eduardo Fuentes  1
Affiliations
Review

RhoA/rho kinase pathway activation in age-associated endothelial cell dysfunction and thrombosis

Iván Palomo et al. J Cell Mol Med. 2024 Apr.

Abstract

The small GTPase RhoA and the downstream Rho kinase (ROCK) regulate several cell functions and pathological processes in the vascular system that contribute to the age-dependent risk of cardiovascular disease, including endothelial dysfunction, excessive permeability, inflammation, impaired angiogenesis, abnormal vasoconstriction, decreased nitric oxide production and apoptosis. Frailty is a loss of physiological reserve and adaptive capacity with advanced age and is accompanied by a pro-inflammatory and pro-oxidative state that promotes vascular dysfunction and thrombosis. This review summarises the role of the RhoA/Rho kinase signalling pathway in endothelial dysfunction, the acquisition of the pro-thrombotic state and vascular ageing. We also discuss the possible role of RhoA/Rho kinase signalling as a promising therapeutic target for the prevention and treatment of age-related cardiovascular disease.

Keywords: RhoA/rho kinase pathway; ageing; cardiovascular disease; endothelial dysfunction; frailty; thrombosis.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
Frailty syndrome. Frailty is characterised by a significant decrease among elderly people in their biological capacity to confront the challenges of daily life. The multiple factors that can trigger the appearance of frailty include lifestyle, genetic background, environmental quality and the existence of co‐morbidities. Frailty status is an important risk factor for chronic diseases associated with old age, which themselves promote the development of frailty.
FIGURE 2
FIGURE 2
Classical RhoA/Rho kinase pathway. Different stimuli can induce RhoA activation, through guanosine exchange factors (GEF) or inhibition through GTPase‐activating protein (GAP). Activated RhoA interacts with the Rho‐binding domain (RBD) domain of Rho kinase, releasing and activating the kinase domain. Activated Rho kinase phosphorylates multiple cell targets, including LIM kinase (LMK) and myosin phosphatase target subunit 1 (MYTP1). Phosphorylated LIMK phosphorylates, and thus inactivates, cofilin, inducing actin polymerization and stabilization. Phosphorylated MYTP1 is inactivated, resulting in the stabilization of the phosphorylated and active form of myosin light chain (MLC), thus promoting actomyosin contraction and cell migration.
FIGURE 3
FIGURE 3
RhoA/Rho kinase pathway activation in age‐related vascular disease. Abnormal activation of the RhoA/Rho kinase pathway has been linked to aging and cellular senescence. Frailty syndrome, directly related with unhealthy ageing, may increase the risk of abnormal RhoA/Rho kinase activation, in turn triggering pathological cell mechanisms that lead to age‐related vascular disease and promote a prothrombotic status in elderly people. MLC, myosin light chain; OE, oxidative stress; VSMCs, vascular smooth muscle cells.
See this image and copyright information in PMC

References

    1. United Nations Department of Economic and Social Affairs Population Division . World Population Ageing 2017 – Highlights (ST/ESA/SER.A/397). 2017.
    1. Garcia‐Garcia FJ, Gutierrez Avila G, Alfaro‐Acha A, et al. The prevalence of frailty syndrome in an older population from Spain. The Toledo study for healthy aging. J Nutr Health Aging. 2011;15(10):852‐856. - PubMed
    1. Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical practice and public health. Lancet. 2019;394(10206):1365‐1375. - PubMed
    1. Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS. Frailty and pre‐frailty in middle‐aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK biobank participants. Lancet Public Health. 2018;3(7):e323‐e332. - PMC - PubMed
    1. Xue QL. The frailty syndrome: definition and natural history. Clin Geriatr Med. 2011;27(1):1‐15. - PMC - PubMed

Publication types

Substances